Factors influencing the incidence of lamotrigine-related skin rash

Annals of Pharmacotherapy

Volumn 33, Issue 10, 1999, Pages 1037-1042

  Wong, Ian C K ^a   Mawer, George E ^b,c   Sander, Josemir W A S ^d  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c David Lewis Centre   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Epilepsy; Lamotrigine; Pharmacoepidemiology; Rash

Indexed keywords

ACETAZOLAMIDE; BENZODIAZEPINE; CARBAMAZEPINE; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; DOSE CALCULATION; DRUG MANUFACTURE; EPILEPSY; ERYTHEMA MULTIFORME; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LEUKOPENIA; LIVER FAILURE; MALE; PRIORITY JOURNAL; RASH; RISK FACTOR; SCHOOL CHILD; STEVENS JOHNSON SYNDROME;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENGLAND; EPILEPSY; EXANTHEMA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TRIAZINES; VALPROIC ACID;

EID: 0032860571     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18422     Document Type: Article

References (27)

1. Marson AG, Kadir ZA, Chadwick DW. New anti-epileptic drugs: a systematic review of their efficacy and tolerability. Br Med J 1996;313:1169-74.
2. Brodie MJ, Richens A, Yuen AWC. UK lamotrigine/carbamazepine monotherapy trial group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
3. Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35:113-21.
4. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
5. Schmidt D, Kramer G. The new anti-convulsant drugs: implications for avoidance of adverse effects. Drug Saf 1994;11:422-31.
6. Committee on Safety of Medicines. Reminder: lamotrigine (Lamictal) and serious skin reactions. Curr Prob Pharmacovigilance 1996;22:12.
7. Yuen A. Safety issues. In: Richens A, ed. International clinical practice series. Clinical update on lamotrigine: a novel anti-epileptic agent. Kent, England: Wells Medical, 1992:69-76.
8. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998:18:281-96.
9. Li LM, Russo M, O'Donoghue M, Sander JWAS, Duncan JS. Allergic skin rash associated with treatment with lamotrigine and concomitant sodium valproate: evidence for an increased risk. Arq Neuropsiquiatr 1996;54:46-9.
10. Campistol J, Geli M, Llistosella E, Molins J, Llobet M. Stevens-Johnson syndrome after lamotrigine treatment. Rev Neurol 1995;23:1236-8.
11. Chaffin JJ, Davis SM. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacother 1997:31:720-3.
12. Fogh K, Mai J. Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal). Seizure 1997:6:63-5.
13. Page RL 2nd, O'Neil MG, Yarbrough DR 3rd, Conradi S. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998:18:392-8.
14. Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine and toxic epidermal necrolysis (letter). Lancet 1996;348:1597.
15. Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996:37:208-12.
16. Vukelic D, Bozinovic D, Tesovic G, Dobric I, Loncaric D, Knezovic I, et al. Lamotrigine and toxic epidermal necrolysis (letter). Dermatology 1997:195:307.
17. Wadelius M, Karlsson T, Wadelius C, Rane A. Lamotrigine and toxic epidermal necrolysis (letter). Lancet 1996:348:1041.
18. Monthly index of medical specialties. London: Haymarket Medical Ltd., January 1994:10.
19. Venulet J. Review: role and place of causality assessment. Pharmacoepidemiol Drug Saf 1992;1:225-34.
20. Altman DG. Practical statistics for medical research. 1st ed. London: Chapman & Hall, 1991:162-5.
21. Brodie MJ. Lamotrigine versus other antiepileptic drugs: a star rating system is born. Epilepsia 1994;35(S5):S41-6.
22. Jawad S, Yuen WC, Peck WC, Hamilton MJ, Oxley JR, Richen A. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:1194-201.
23. Kasteleijn-Nolst Trenite DGA, Edelbroek PM. Antiepileptic drug treatment in the nineties in the Netherlands. Pharm World Sci 1997:19:60-9.
24. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997:38:881-6.
25. Tavernor S, Wong ICK, Brown SW, Newton R. Rechallenge with lamotrigine after initial rash. Seizure 1995:4:67-71.
26. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997;43:457-65.
27. Dean JA, Dean AG, Burton AH, Dicker RC. Epi-Info. Version 5: a word processing, database, and statistics program for epidemiology on microcomputers. USD, Incorporated. Stone Mountain, GA, 1990.